The FDA Just Killed Your Access to Tirzepatide: The Retatrutide Revolution
The landscape of peptide therapy is shifting overnight. If you rely on compounded GLP-1 medications, your access is under immediate […]
The landscape of peptide therapy is shifting overnight. If you rely on compounded GLP-1 medications, your access is under immediate […]
I deployed the Wolverine Stack (BPC-157 & TB-500) to heal my tendons and added CJC-1295 and Ipamorelin to trigger a
Retatrutide is the first triple G agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously. Wayne Stevenson and Victoria break down the Phase 3 TRIUMPH trial data, the 25% weight loss numbers, muscle loss risks, and the Builder’s 4-pillar protection protocol.
KLOW vs GLOW Peptide Stacks: The Science Nobody Explains Two branded peptide stacks are dominating the regenerative health conversation in
The FDA removed 11 peptides from the Category 2 Do-Not-Compound list on April 15, 2026. BPC-157, TB-500, MOTS-c and more are now under PCAC review. Here’s what it means.
Wayne Stevenson analyzes CJC-1295 DAC vs. Tesamorelin: The Visceral Belly Fat Battle for metabolic health and muscle preservation.
I lost 48 pounds using Mounjaro, but what I discovered in the footnotes of the clinical trial data was alarming—severe lean mass wasting. Here is the 4-pillar prevention protocol I designed to lock in nitrogen balance, trigger protein synthesis, and protect structural strength.
The FDA removed 12 peptides from Category 2, but that does NOT mean they’re approved. Full regulatory breakdown of BPC-157, TB-500, and GHK-Cu status for 2026. Builder Blueprint case study by Wayne Stevenson.
Wayne Stevenson analyzes The Wolverine Stack: A Builders Case Study on BPC-157 + TB-500 for metabolic health and muscle preservation.
Wayne Stevenson analyzes I Lost 38 lbs on Mounjaro While Building Houses — My Complete 26-Week Protocol for metabolic health and muscle preservation.